Phocas Financial Corp. Pacira Bio Sciences, Inc. Transaction History

Phocas Financial Corp.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 10, 2023	SELL	$30.68 - $40.09 $2.73 Million - $3.57 Million	-89,064 Reduced 66.87%	44,131 $1.35 Million
Q2 2023 Jul 12, 2023	BUY	$36.12 - $47.5 $1.33 Million - $1.75 Million	36,839 Added 38.23%	133,195 $5.34 Million
Q1 2023 Apr 13, 2023	BUY	$35.53 - $43.38 $33,469 - $40,863	942 Added 0.99%	96,356 $3.93 Million
Q4 2022 Jan 10, 2023	SELL	$38.19 - $57.45 $1,107 - $1,666	-29 Reduced 0.03%	95,414 $0
Q3 2022 Oct 14, 2022	BUY	$51.24 - $58.89 $155,154 - $178,318	3,028 Added 3.28%	95,443 $5.08 Million
Q2 2022 Aug 15, 2022	SELL	$51.49 - $81.64 $53,189 - $84,334	-1,033 Reduced 1.11%	92,415 $5.39 Million
Q1 2022 May 25, 2022	BUY	$60.03 - $76.49 $5.61 Million - $7.15 Million	93,448 New	93,448 $7.13 Million

260

49.5M

1.03M

139K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.17B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Phocas Financial Corp., based on Form 13F filings with the SEC.

Stay updated on Phocas Financial Corp. with notifications on news.